GeneDx Holdings financials
$75.79−11.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $114.4M | $102.3M | $121.0M | $116.7M | $102.7M | $87.1M | $95.6M | $76.9M | $70.5M | $62.4M | $57.4M | $53.3M |
| Gross profit | $78.2M | $68.2M | $84.3M | $84.5M | $70.9M | $58.5M | $66.2M | $47.8M | $43.0M | $37.4M | $30.8M | $25.3M |
| Gross margin | 68.4% | 66.7% | 69.6% | 72.4% | 69.0% | 67.1% | 69.2% | 62.2% | 60.9% | 59.9% | 53.6% | 47.4% |
| Operating income | -$17.5M | -$57.5M | -$14.2M | -$3.3M | $9.0M | -$4.6M | $8.8M | -$7.8M | -$10.6M | -$13.7M | -$25.6M | -$43.0M |
| Net income | -$17.7M | -$63.6M | -$17.7M | -$7.6M | $10.8M | -$6.5M | $5.4M | -$8.3M | -$29.2M | -$20.2M | -$25.8M | -$42.3M |
| Net margin | −15.5% | −62.2% | −14.6% | −6.5% | 10.5% | −7.4% | 5.7% | −10.8% | −41.4% | −32.4% | −44.9% | −79.3% |
| Diluted EPS | $-0.60 | $-2.16 | $-0.63 | $-0.27 | $0.36 | $-0.23 | $0.20 | $-0.31 | $-1.10 | $-0.78 | $-0.99 | $-1.64 |
| EBITDA | -$10.7M | -$19.4M | -$7.4M | $3.2M | $15.2M | $1.1M | $14.4M | -$1.9M | -$5.4M | -$8.4M | -$25.6M | -$26.0M |
| Operating cash flow | -$29.0M | -$32.4M | -$3.1M | $15.8M | $10.4M | $10.2M | -$3.2M | -$4.4M | -$4.5M | -$16.4M | -$29.9M | -$41.2M |
| Free cash flow | -$39.1M | -$38.9M | -$7.4M | $9.6M | $8.1M | $4.1M | -$6.2M | -$5.0M | -$5.9M | -$16.9M | -$32.2M | -$41.3M |
| Diluted shares | 29.7M | 29.3M | 27.9M | 28.8M | 29.8M | 28.1M | 27.8M | 27.1M | 26.6M | 26.1M | 26.0M | 25.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $60.3M | $93.9M | $105.0M | $96.0M | $74.1M | $99.7M |
| Short-term investments | $72.2M | $76.8M | $66.3M | $59.1M | $60.4M | $59.5M |
| Total debt | $96.8M | $96.7M | $48.2M | $51.6M | $51.7M | $51.8M |
| Total assets | $481.5M | $506.3M | $523.7M | $493.9M | $463.9M | $446.4M |
| Total liabilities | $237.3M | $252.2M | $215.5M | $201.6M | $186.7M | $189.0M |
| Shareholders' equity | $244.2M | $254.1M | $308.2M | $292.3M | $277.1M | $257.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology